The Weekly Recap 10/10/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funding, enter new partnerships, achieve clinical and regulatory milestones, and much more on the road to LSI USA ‘26 in Dana Point (March 16–20).

Acorai

Reported positive results from the 1,600-patient CAPTURE-HF study evaluating its non-invasive, multi-sensor heart failure monitoring platform. The study, presented at HFSA 2025, demonstrated high sensitivity and strong negative predictive value for ruling out elevated Pulmonary Capillary Wedge Pressure (PCWP) and Right Atrial Pressure (RAP).

Askel Healthcare

Raised €1.76M in its latest crowdfunding round to accelerate clinical development of the COPLA Cartilage implant. The financing, backed by 625 investors, supports the advancement of Askel’s Class III universal implant, designed to repair knee cartilage defects and help patients return to active lifestyles faster.

AtaCor Medical

Secured up to $75M in financing to support the U.S. pivotal trial of its parasternal extravascular implantable cardioverter-defibrillator (EV-ICD) system. The trial will evaluate the system, which consists of the Atala™ lead and an implantable pulse generator, for the treatment of life-threatening ventricular tachyarrhythmias.

Avobis Bio

Received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for AVB-114, its implantable cell therapy for Crohn’s perianal fistulas. The designation, supported by positive phase I and II clinical data, provides intensive regulatory support to accelerate phase III planning and advance AVB-114 toward patients lacking effective treatment options.

Dova Health Intelligence

Announced a collaboration with Mayo Clinic to advance the development and validation of its AI-powered DovaVision UC Mayo Endoscopic Score tool for automated ulcerative colitis assessment. The partnership supports regulatory preparation and aims to standardize endoscopic scoring to enhance precision in both clinical and research settings.

Innitius

Appointed Maria Nyåkern, PhD, to the Board of Directors to strengthen clinical and regulatory strategy. A recognized expert in EU MDR and AI in healthcare, Nyåkern brings over two decades of experience in evidence generation and medtech regulation to support Innitius’ mission to advance innovation in women’s health.

Medical Microinstruments

Completed the world’s first robotic microsurgical intracranial brain surgeries using the Syman^Ⓡ Surgical System. The first-in-human cases mark a major milestone in robotic neurosurgery and support the system’s expansion into highly complex surgical domains like Moyamoya disease.

MediView XR

Closed a $24M Series A round to advance augmented reality–based surgical navigation and imaging. The funding, led by GE HealthCare, Cleveland Clinic, and Mayo Clinic, accelerates the commercialization of MediView’s FDA-cleared platform that fuses CT and live ultrasound to provide clinicians with real-time 3D “X-ray vision” during procedures.

Methinks AI

Received its second FDA 510(k) clearance of the year, this time for Methinks CTA Stroke, its AI solution for detecting suspected large vessel occlusions (LVOs) via CT angiography scans. The new clearance complements the previously approved NCCT-based tool, enabling a comprehensive and accessible stroke triage platform across diverse healthcare settings.

Neuronoff

Closed an oversubscribed $4.5M financing round to advance the Injectrode^Ⓡ platform toward FDA clearance and a limited U.S. launch in 2026. The funding supports scaling production of the minimally invasive, drug-free neuromodulation system for chronic pain, and establishes a new subsidiary targeting an undisclosed indication affecting 16 million U.S. adults.

Oath Surgical

Raised a $24M Series A to expand its national network of surgeon-owned, AI-powered surgical centers and advance the OathOS operating system. The funding enables growth into new markets and specialties like oncology and supports the company’s mission to reduce costs, improve outcomes, and reimagine surgical care through value-based, tech-enabled innovation.

Qaelon Medical

Appointed Dr. Marylise Boutros to its Scientific Advisory Board to help Qaelon Medical advance its real-time surgical leak detection technology for gastrointestinal and colorectal procedures. Dr. Boutros is a renowned colorectal surgeon and researcher at Cleveland Clinic Florida, strengthening Qaelon’s mission to enhance surgical outcomes through real-time digital innovation.

Remedy Robotics

Completed the world’s first fully remote, in-human endovascular procedures using the Remedy N1 System. This first-of-its-kind robotic platform combines AI and remote operability to transform stroke and cardiovascular intervention by expanding access, improving precision, and reducing treatment delays worldwide.

RevBio

Was awarded a $2.2M Phase II NIH grant to advance the development of TETRANITE^Ⓡ for treating vertebral compression fractures. The grant supports preclinical testing of TETRANITE,  a patented, synthetic, injectable, self-setting, and osteoconductive bone adhesive.

Samay

Announced a partnership with Chiesi Farmaceutici to co-develop new algorithms for early detection of small airway disease. The collaboration includes a pilot study using Samay’s wearable Sylvee chest sensor and supports the company’s mission to broaden diagnostic capabilities in respiratory health ahead of its planned Latin American launch in 2028.

Tensive

Published 24-month follow-up data showing sustained positive outcomes with its REGENERA™/SOFTAG™ breast implants in Breast Cancer journal. The results demonstrate ongoing tissue regeneration, high investigator and patient satisfaction, and an excellent safety profile, supporting momentum toward regulatory submissions in 2026 and potential approval by early 2027.

Vektor Medical

Secured CE Mark for vMap^Ⓡ, its AI-powered, non-invasive arrhythmia mapping system. The clearance enables European commercialization and expands access to rapid, data-driven insights that help electrophysiologists identify arrhythmia sources and improve ablation outcomes.

Xenocor

Was awarded a U.S. patent for its medical borescope and tip assembly technology. The newly granted patent covers a range of novel features, including the integration of electromagnetic interference (EMI) shielding within the Saberscope^Ⓡ tip assembly. 

Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.